WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Apr. 17, 2018--
Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company
focused on applying monoclonal antibody (mAb) immunotherapies to address
serious infectious diseases, announced today that the company will
present five scientific posters at the 28th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain
from April 21 – 24, 2018. The posters will highlight new research
findings and supportive data across all mAb programs in Arsanis’
The following abstracts will be presented at ECCMID as an exchange of
scientific and clinical information (all times CEST):
Presentation: #1006; Sunday, April 22, 1:30 – 2:30 p.m.
of Staphylococcus aureus links nasal carriage to lower airway
colonization in mechanically ventilated patients
Lead author: L.
Presentation: #0021; Saturday, April 21, 3:30 – 4:30 p.m.
characterization of highly potent human monoclonal antibodies targeting
different antigenic sites on the pre-fusion RSV-F protein
author: H. Rouha
Presentation: #1403; Monday, April 23, 12:30 – 1:30 p.m.
sensitivity of Klebsiella pneumoniae correlates with the
O-serotype and determines the mechanisms required for mAb-based
protection from infection
Lead author: G. Nagy
Presentation: #0913; Sunday, April 22, 12:30 – 1:30 p.m.
is the dominant clone among Escherichia coli airway colonizers in
mechanically ventilated patients: a prospective study
Poster Presentation: #1409; Monday, April 23, 12:30 – 1:30 p.m.
of the role of the complement system in killing Escherichia coli
by using in vitro reconstituted complement pathways
author: M. Mutti
Arsanis, Inc. is a clinical-stage
biopharmaceutical company focused on applying monoclonal antibody (mAb)
immunotherapies to address serious infectious diseases. A deep
understanding of the pathogenesis of infection, paired with access to
some of the most advanced mAb discovery techniques and platforms
available today, has positioned Arsanis to build and advance a pipeline
of novel mAbs with multiple mechanisms of action and high potency
against their intended targets. The company’s lead clinical program,
ASN100, is aimed at serious Staphylococcus aureus infections
and is being evaluated in a Phase 2 clinical trial for the prevention of S.
aureus pneumonia in high-risk, mechanically ventilated
patients. In addition to ASN100, the Arsanis preclinical pipeline is
comprised of mAbs targeting multiple serious bacterial and viral
pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with
European research and preclinical development operations headquartered
in Vienna, Austria (Arsanis Biosciences GmbH).
For more information, please visit the Arsanis website at www.arsanis.com.
Cautionary Note Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding Arsanis’ plans,
strategies and expectations for the clinical development of its mAb
programs; the expected benefits of the option and license agreement for
ASN200; and the potential benefit of its strategic plans and focus. The
words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,”
“hope,” “strategy,” “milestone,” “will,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Arsanis' current expectations and beliefs. For example,
there can be no guarantee that any mAb programs Arsanis is developing
will successfully commence or complete necessary preclinical and
clinical development phases, or that development of any of Arsanis'
product candidates will successfully continue. There can be no guarantee
that any positive developments in Arsanis' business will result in stock
price appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be affected
by risks and uncertainties relating to a number of other important
factors, including: Arsanis' results of clinical trials and preclinical
studies, including subsequent analysis of existing data and new data
received from ongoing and future studies; the content and timing of
decisions made by the U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and publication
review bodies; Arsanis' ability to obtain and maintain requisite
regulatory approvals and to enroll patients in its planned and ongoing
clinical trials; unplanned cash requirements and expenditures;
competitive factors; Arsanis' ability to obtain, maintain and enforce
patent and other intellectual property protection for any product
candidates it is developing; Arsanis' ability to maintain key
collaborations; and general economic and market conditions. These and
other risks are described in greater detail under the caption "Risk
Factors" included in Arsanis’ public filings with the Securities and
Exchange Commission. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Arsanis expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417005151/en/
Source: Arsanis, Inc.
Ten Bridge Communications
Michael Gray, 781-819-5201
Operating and Chief Financial Officer